慢性肺曲霉病的诊治进展

慢性肺曲霉病(chronic pulmonary Aspergillosis,CPA)指慢性肺部曲霉菌感染,病程超过3个月,常发生在已有肺部疾病或轻度免疫抑制的患者,并需要比较长的治疗时间。近年来,临床医生对该病的认识不断提高。美国感染病学会曾于2000年提出了曲霉菌病的治疗共识,并在2008年进行了更新,此外尚无 CPA 临床指南发布,2016年欧洲临床微生物学与感染性疾病学会和欧洲呼吸学会(European Society of Clinical Microbiology and Infectious Diseases/European Respiratory Society,ESCMID/ERS)总结了关于 CPA 的前期研究成果,联合制定并发布了首个 CPA 指南。本文对 CPA 的最新诊治进展阐述如下。

The progress of diagnosis and treatment of chronic pulmonary Aspergillosis

Chronic pulmonary Aspergillosis (CPA) refers to chronic pulmonary Aspergillus infection,and the duration of CPA is usually more than 3 months,CPA occurs in patients with underlying lung disease or mild immunosuppression and needs relatively long treatment duration.In recent years,the clinician′s understanding of the disease is more and more improved.The Infectious Diseases Society of America(IDSA)has presented the consensus of the treatment of aspergillosis in 2000,and was updated in 2008.In addition,there is no CPA published clinical guidelines.Recently,an expert group from the European Society of Clinical Microbiology and Infection Diseases (ESCMID) and from the European Respiratory Society (ERS) summarized the results of preliminary research on CPA,and released a rationale and clinical guideline of CPA.This article is a review of the latest progress of diagnosis and treatment of CPA.